30 results
8-K
EX-99.1
GOSS
Gossamer Bio Inc
12 Mar 24
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan
4:01pm
medical associations, including the American Thoracic Society, the American College of Chest Physicians, and the International Society for Heart and Lung
8-K
EX-99.1
GOSS
Gossamer Bio Inc
9 Nov 23
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
7:31am
Respiratory Society International Congress 2023. These data provide encouraging clinical evidence of seralutinib's ability to improve the pulmonary … , sub-study of the successful Phase 2 TORREY Study of seralutinib in patients with PAH was presented in September at the European Respiratory Society
8-K
EX-99.1
GOSS
Gossamer Bio Inc
3 Nov 22
Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update
4:00pm
developed preclinical programs presented at recent medical conferences:
◦International Cytokine & Interferon Society (September 2022):
Identification … Models
Poster highlighting a third internally developed program to be presented at the upcoming Society for Immunotherapy of Cancer, or SITC 2022
8-K
EX-99.1
GOSS
Gossamer Bio Inc
12 Nov 19
Gossamer Bio Announces Third Quarter 2019 Financial Results
4:10pm
Exacerbation Before Initiation of Biologic Therapy: A Real-world Experience
A poster supporting GB001 was presented at the European Respiratory Society … -in-progress poster at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, held November 6-10 in National Harbor, Maryland. This poster can now
8-K
EX-99.1
GOSS
Gossamer Bio Inc
10 Nov 20
Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update
4:14pm
) -
- GB1275: Two posters with data from ongoing Phase 1/2 KEYNOTE-A36 clinical trial in advanced solid tumors presented at Society for Immunotherapy of Cancer … : Oral CD11b Modulator for Oncology Indications
Two GB1275 posters are being presented at the 35th Annual Meeting of the Society for Immunotherapy
8-K
EX-99.1
7afmnsok6d
6 May 21
Gossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update
8:06am
8-K
EX-99.1
wabapd05en3r45y62dxl
7 May 24
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
4:02pm
8-K
EX-99.1
ent1u5l1c811qdewc
9 Aug 21
Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update
4:27pm
8-K
EX-99.1
n039hrxy
6 May 24
Entry into a Material Definitive Agreement
7:31am
8-K
EX-99.1
jcor7 ijrepddxkl
12 May 20
Gossamer Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
4:18pm
424B5
pz6w h048m
19 May 20
Prospectus supplement for primary offering
5:08pm
424B5
nok8qarc6bb72c4akdm8
18 May 20
Prospectus supplement for primary offering
4:11pm
S-1
EX-10.15
vrj6vcpc
21 Dec 18
IPO registration
4:39pm
DRS
EX-10.11
y2v dnmeguqpr74n8
11 Oct 18
Draft registration statement
12:00am
424B5
tljwb5e
19 May 20
Prospectus supplement for primary offering
5:11pm
424B5
nxyac 1mbtsywke
18 May 20
Prospectus supplement for primary offering
4:16pm
10-K
6wo9pj1g yhm
22 Mar 19
Annual report
4:45pm